Clinical trial NCT01156597: Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes
Official title: Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Keywords: diabetes
dyslipidemia
pioglitazone
HDL-Cholesterol
Reverse cholesterol transport
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Takeda Pharmaceuticals North America, Inc.
First posted: 2010-07-05
Enrollment: 30
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Metabolic defects contributing to the development of type 2 diabetes (T2D) are relative insulin insufficiency and insulin resistance that are associated with a cluster of abnormalities that increase the risk for cardiovascular disease including dyslipidemia, inflammation, hemodynamic changes and endothelial dysfunction. The dyslipidemia associated with T2D is characterized by elevated triglycerides and decreased high-density lipoprotein-cholesterol (HDL). The ability of the insulin sensitizing agent pioglitazone (ACTOS®) , to improve hyperglycemia in subjects with T2D is now well established. Pioglitazone functions as a PPAR-γ (peroxisome proliferator-activated receptor gamma) agonists and this class of drugs have demonstrated several other potential benefits, beyond glucose homeostasis. Specifically pioglitazone can improve diabetic dyslipidemia by increasing HDL cholesterol and lowing triglycerides. A potential beneficial effect on reverse cholesterol transport may be mediated by the increased HDL levels. This proposal aims to examine the effect of PPAR-γ activation by PIO on various aspects of reverse cholesterol transport by testing the hypothesis that PIO treatment affects key steps in the reverse cholesterol transport pathway either directly, through induction of protein expression, or indirectly, by altering HDL structure and composition leading to increase cholesterol flux through this pathway.

Detailed description: Thiazolidinediones (TZDs) are pharmacological ligands for the nuclear receptor peroxisome-proliferator-activated receptor gamma (PPAR-γ). When activated, the receptor binds with response elements on DNA, altering transcription of a variety of genes that regulate carbohydrate and lipid metabolism1. The hypoglycemic and insulin sensitizing effects of PIO and other TZD compounds are well established2-4. The most prominent effect is increased insulin-stimulated glucose uptake by skeletal muscle cells5,6. The receptor is most highly expressed in adipocytes, while expression in myocytes is comparatively minor. Therefore, the increase in glucose uptake by muscle may largely be an indirect effect mediated through TZD interaction with adipocytes7-9. Candidates for the intermediary signal between fat and muscle include leptin, free fatty acids, tumor necrosis factor-α, adiponectin, and resistin.

T2D is associated with a cluster of lipid and lipoprotein abnormalities including reduced HDL, elevated triglycerides and a predominance of small dense LDL particles10. Altered metabolism of triglyceride rich lipoproteins is crucial in the pathophysiology of diabetic dyslipidemia. Alterations include increased hepatic production and delayed clearance from plasma of large very low density lipoproteins (VLDL) and intestinal chylomicrons. Increased levels of these particles also results in increased production of small dense low density lipoprotein (LDL). The reduction in high density lipoprotein (HDL) associated with T2D appears related to CETP-mediated transfer of cholesterol from HDL to triglyceride rich particles in exchange for triglyceride. The triglyceride rich HDL are hydrolyzed by hepatic lipase, reducing particles size, then more rapidly cleared from the circulation11. Reduced HDL is due to mostly a decrease in HDL2, however, there are increased levels of small HDL3 12.

In addition to their ability to induce insulin sensitivity in T2D subjects, TZDs also have certain lipid benefits. HDL cholesterol concentrations are often increased with TZD therapy and triglyceride concentrations frequently fall13. A nonrandomized clinical comparison of potential differences in lipid effects among TZDs14 demonstrated the beneficial effect on lipids was most with pioglitazone (PIO) and least with rosiglitazone (ROSI)15. These observations were confirmed in a study investigating the lipid-lowering effects of TZDs showing that PIO was associated with significantly greater improvements in triglycerides, HDL cholesterol, non-HDL cholesterol, and LDL particle size compared with ROSI 16. The mechanism(s) by which these agents exert differential effects on the lipid profile are not clearly understood. Whether these differences in lipid effects translate into differences for the risk of CVD is not clear. Trials to determine the effects of pioglitazone and rosiglitazone on CVD outcomes are underway and should identify any cardiovascular benefits of the two drugs.

Lipid metabolism plays a central role in the development of atherosclerosis. Elevated LDL and decreased HDL cholesterol are important risk factors for the development of coronary artery disease (CAD). The major cholesterol-carrying lipoprotein in the blood is LDL and many studies have shown the independent relationship between LDL cholesterol and atherosclerosis in both non-diabetic and diabetic subjects17. The metabolism of HDL, which are inversely related to risk of atherosclerotic cardiovascular disease, involves a complex interplay of factors regulating HDL synthesis, intravascular remodeling, and catabolism18. The anti-atherogenic property of HDL has been attributed, at least in part, to the ability of HDL to promote cholesterol removal (efflux) from cells, the first step in the reverse cholesterol transport pathway 19.

Reduced HDL in T2D results from increased clearance of small HDL particles20, and PIO treatment of these subjects raises HDL levels by 10-15% through as yet poorly defined mechanisms. Studies by Ginsberg and colleagues21, in an elegant study, examined the effects PIO treatment in patients with T2D on various aspects of lipoprotein metabolism. PIO raised HDL cholesterol levels 14%, but no change in apoA-I production rates, or fall in apoA-I synthetic rates were observed during PIO therapy22. ApoA-I synthesis is regulated by several transcription factors, including PPAR-α; there is no evidence that PPAR-α plays a role in apoA-I synthesis in vivo, although both PIO and ROSI have been reported to stimulate apoA-I secretion from HepG2 cells23. The authors suggest that the rise in HDL may have resulted from reduced CETP-mediated exchange of VLDL triglycerides for HDL cholesterol, concomitant with the PIO-associated fall in VLDL levels or a reduced the mass or activity of HL thus increasing HDL levels. There are no published data regarding PPAR-γ agonists on HL activity, but the authors found no change in HL mass in preheparin serum by PIO treatment. A final possibility proposed by these authors was PPAR-γ signaling may play a role in stimulating expression of the gene encoding ABCA1 which could increase the flux of cholesterol from cells onto nascent apoA-I.

Study Aims Characterize the structural and functional changes in plasma lipids and lipoproteins in T2D subjects before and after PIO treatment. A major emphasis will compare serum HDL function as related to reverse cholesterol transport by plasma lipoproteins at baseline and after PIO treatment.

We hypothesize that increased levels of HDL resulting from PIO therapy will affect particle size, density distribution and the lipid and lipoprotein composition of HDL and that such changes may alter the activity of several key steps involved in reverse cholesterol transport, namely the ability to promote cellular cholesterol efflux, cholesterol esterification by LCAT and transport of esterified cholesterol from HDL to the apoB containing lipoproteins.

Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes, men and women, WHO criteria, aged 35-70 years
* HbA1c 7.5-10.0%
* BMI 26-39 Kg/m2
* Either receiving dietary therapy only or monotherapy with either sulfonylurea or metformin
* Already on statin therapy

Exclusion Criteria:

* Cardiovascular disease
* Renal disease
* Other systemic disease
* Abnormal liver function tests (ALT or AST\>1.5 X ULN)
* Uncontrolled hypertension (BP \>160/110)
* Triglyceride levels \>400 mg/dl
* Lipid modifying drugs; fibrates, ezetimibe, niacin, bile sequestrants, but not statins (see below),
* Estrogen treatment or thyroid disease
* Psychiatric condition or substance abuse

Primary outcomes:
measure: Increased HDL-Cholesterol and Decreased Triglycerides
timeFrame: 24 weeks
Secondary outcomes:
measure: HDL Apolipoprotein Levels at Study End-point
timeFrame: 24 weeks
measure: Cholesterol Efflux Capacity of HDL
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Miami
country: United States
facility: Diabetes Research Institute
state: Florida
Study officials:
affiliation: University of Miami
name: Armando J Mendez, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Miami
name: Ronald Goldberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med. 2001;52:239-57. doi: 10.1146/annurev.med.52.1.239.
citation: Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract. 2004 Feb;58(2):192-200. doi: 10.1111/j.1368-5031.2004.0108.x.
citation: Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther. 2003;25 Suppl B:B64-80. doi: 10.1016/s0149-2918(03)80243-6.
citation: Charbonnel B, Roden M, Urquhart R, Mariz S, Johns D, Mihm M, Widel M, Tan M. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia. 2005 Mar;48(3):553-60. doi: 10.1007/s00125-004-1651-9. Epub 2005 Mar 1.
citation: Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab. 2005 May;288(5):E930-4. doi: 10.1152/ajpendo.00522.2004. Epub 2005 Jan 4.